PLPC:NASDAQPreformed Line Products Company Analysis
Data as of 2026-04-24 - not real-time
$351.17
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Preformed Line Products Company has surged to an all‑time high, driven by a 1‑year price appreciation of well over 100% and a recent breakout to its 52‑week peak. Technical indicators reinforce the momentum: the short‑term moving average sits comfortably above the medium‑term average, the RSI is deep in overbought territory, and the MACD histogram remains positive, all pointing to a bullish trend. Volume, however, is on a downtrend, suggesting that the rally may be losing steam and could be vulnerable to a pullback. The stock’s beta is markedly above the market average, and 30‑day volatility exceeds 50%, underscoring heightened price swings.
Fundamentally, the company trades at a price‑to‑earnings multiple far above the industry norm and well above its discounted cash‑flow estimate, indicating that the market has priced in strong growth expectations. Margins are modest, cash flow is positive but modest relative to debt, and the dividend yield is low with a very conservative payout ratio, supporting dividend sustainability. The blend of aggressive valuation, elevated volatility, and global operational exposure creates a risk profile that leans toward the higher end of the spectrum.
Fundamentally, the company trades at a price‑to‑earnings multiple far above the industry norm and well above its discounted cash‑flow estimate, indicating that the market has priced in strong growth expectations. Margins are modest, cash flow is positive but modest relative to debt, and the dividend yield is low with a very conservative payout ratio, supporting dividend sustainability. The blend of aggressive valuation, elevated volatility, and global operational exposure creates a risk profile that leans toward the higher end of the spectrum.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price near 52‑week high with bullish technicals
- Decreasing volume indicating potential short‑term weakness
- Elevated volatility and beta increasing downside risk
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong growth narrative priced into the stock
- Modest profitability and cash flow versus debt load
- Sustained dividend with low payout ratio
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Significant overvaluation relative to fundamentals and DCF
- High valuation multiples and sector cyclicality
- Persistent high volatility and beta amplifying market risk
Key Metrics & Analysis
Financial Health
Revenue Growth3.60%
Profit Margin5.27%
P/E Ratio49.3
ROE7.87%
ROA5.57%
Debt/Equity10.04
P/B Ratio3.6
Op. Cash Flow$73.5M
Free Cash Flow$9.2M
Industry P/E31.1
Technical Analysis
TrendBullish
RSI71.2
Support$259.80
Resistance$352.37
MA 20$306.40
MA 50$279.00
MA 200$223.91
MACDBullish
VolumeDecreasing
Fear & Greed Index88.02
Valuation
Fair Value$36.82
Target Price$275.00
Upside/Downside-21.69%
GradeOvervalued
TypeGrowth
Dividend Yield0.25%
Risk Assessment
Beta1.59
Volatility54.97%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.